V116 + PPSV23
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pneumococcal Disease
Conditions
Pneumococcal Disease
Trial Timeline
Nov 7, 2022 → Feb 7, 2025
NCT ID
NCT05569954About V116 + PPSV23
V116 + PPSV23 is a phase 3 stage product being developed by Merck for Pneumococcal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05569954. Target conditions include Pneumococcal Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06177912 | Phase 3 | Completed |
| NCT05633992 | Phase 3 | Completed |
| NCT05569954 | Phase 3 | Completed |
| NCT05464420 | Phase 3 | Completed |
Competing Products
20 competing products in Pneumococcal Disease